TECHNESCAN MAG3
Details
- Status
- Prescription
- First Approved
- 1990-06-15
- Routes
- INJECTION
- Dosage Forms
- INJECTABLE
TECHNESCAN MAG3 Approval History
What TECHNESCAN MAG3 Treats
5 indicationsTECHNESCAN MAG3 is approved for 5 conditions since its original approval in 1990. These indications span multiple therapeutic areas including oncology, immunology, and more.
- Congenital Abnormality
- Acquired Abnormality
- Renal Failure
- Urinary Tract Obstruction
- Calculi
Active Pipeline
Ongoing clinical trials by development phase
Key Completed Trials
Completed studies with published results, ranked by significance
Trial Timeline
Full development history with FDA approval milestones
Understanding FDA Approval Types
| Count | Type | What it means |
|---|---|---|
| - | ORIG | Original approval - drug first enters market |
| - | SUPPL - Efficacy | New indication (new disease/condition approved) |
| - | SUPPL - Labeling | Label text changes (warnings, dosing updates) |
| - | SUPPL - Manufacturing | Production changes (new facility) |
| - | SUPPL - Chemistry | Formulation changes (new dosage strength) |
Green lines in the timeline show ORIG and Efficacy approvals - the clinically meaningful milestones.
TECHNESCAN MAG3 FDA Label Details
ProIndications & Usage
Technetium Tc 99m mertiatide is a renal imaging agent for use in the diagnosis of congenital and acquired abnormalities, renal failure, urinary tract obstruction, and calculi in adults and pediatric patients. (See Pediatric Use. ) It is a diagnostic aid in providing renal function, split function, renal angiograms, and renogram curves for whole kidney and renal cortex.
Want competitive intelligence?
See who's developing similar drugs and track their progress
Data Sources
Data sourced from official FDA and NIH databases. Click links to verify on original sources.